Study of autoantibody against to p90, p16 and IMP1 as tumor markers in human esophageal cancer by ELISA

• Main Authors: Yea-Huey, 張雅惠
• Other Authors: Ling-Yun Chen
• Format: Others
• Language: zh-TW
• Published: 2007
• Online Access: http://ndltd.ncl.edu.tw/handle/81614389987896487314

碩士 === 中山醫學大學 === 生化暨生物科技研究所 === 95 === Esophageal cancer is the eighth major cancer worldwide. Esophageal cancer ranks the ninth cause of death from all cancers in Taiwan. Most cancer patients were not established to diagnose until later period. They were in the situation with poor prognosis. Therefore, it is important in the early diagnosis of esophageal cancer patients. Some scholars were looking for the tumor antigens with the cancer patients'' sera by SEREX. The level of tumor antigens which are tumor-specific antigens or tumor-associated antigens can help diagnose the change or prognosis of the cancer as the tracked tool. The person who we went to school with in our laboratory had screened seven autoantibodies against TAAs including IMP1, Cyclin B1, Ras, CSK, Erbb2, p90, p16 in 30 esophageal cancer patients’ sera by ELISA. Three autontibody to p90, p16 or IMP1 presents in high positive reactors. The percentages of positive reactors to p90, p16 or IMP1 were higher relatively. The percentages were 10%, 26.6% and 26.6% respectively. It seems that p90, p16 and IMP1 might be diagnosed as tumor markers of the esophageal cancer. Because the specimens are too little, we increase from 30 to 120 specimens to confirm if p90, p16 and IMP1 are useful tumor markers in esophageal cancer. We use both original sera and sera treated with ammonium sulfate that precipitates the serum proteins by improving sensitivity. Two different cutoff values are normal cutoff value (Mean +2SD) and lower cutoff value (Mean +SD) respectively. We compare the percentage of positive reactors in patients and healthy individuals. And we contrast between original sera and sera from ammonium sulfate. By normal cutoff value (Mean +2SD), the results show that autoantibody to p90, p16 and IMP1 were found in 3.33%, 0%, 0% of healthy individuals’ and 3.33%, 5.00%, 8.33% of patients’ original sera respectively. And the lower cutoff value (Mean +SD) analyses p90, p16 and IMP1. They appear 23.33% , 23.33% , 20.00% in healthy individuals and 9.17%, 14.17%, 21.67% in patients respectively. We find that lower cutoff value increases percentages of positive reactors but decreases the accuracy obviously. And normal cutoff value (Mean+2SD) analyses p90, p16 or IMP1 in sera treated with the ammonium sulfate. They appear 0%, 0%, 3.33% in healthy individuals and 3.33%, 5.83%, 10.00% in patients respectively. By lower cutoff value (Mean +SD), percentage of positive reactors are 16.67%, 20.00%, 20.00% in healthy individuals and 10.00%, 15.83%, 25.00% in patients. We also find that lower cutoff value increases the percentages of positive reactors but decreases the accuracy obviously. In order to increase the accuracy of positive reactors, we cross the all results. We find the sera treated with ammonium sulfate. Among the healthy individuals or patients appear p90 or p16 autoantibody, p90 and p16 which appear at the same time are 10% in healthy individuals and 50% in patients. It is possible that both of p90 and p16 appear at the same time to screen the esophageal cancer. These results are absent in the original sera.